Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
Offer, Steven M. , Wegner, Natalie J., Fossum, Croix C. , Wang, Kangsheng , Diasio, Robert B. , Offer, Steven M

Mayo Clinic

Cancer Research | January 17, 2013 | Volume: 73 | Issue: 6 | Pages: 1958-1968

10.1158/0008-5472.can-12-3858 | PMID 23328581 Get It

Abstract In the 45 years since its development, the pyrimidine analog 5-fluorouracil (5-FU) has become an integral component of many cancer treatments, most notably for the management of colorectal cancer. An appreciable fraction of patients who receive 5-FU suffer severe adverse toxicities, which in extreme cases may result in death. Dihydropyrimidine dehydrogenase (DPD, encoded by DPYD) rapidly degrades 85% of administered 5-FU, and as such, limits the amount of drug available for conversion into active metabolites. Clinical studies have suggested that genetic variations in DPYD increase the risk for 5-FU toxicity, however, there is not a clear consensus about which variations are relevant predictors. In the present study, DPYD variants were expressed in mammalian cells, and the enzymatic activity of expressed protein was determined relative to wild-type (WT). Relative sensitivity to 5-FU for cells expressing DPYD variations was also measured. The DPYD*2A variant (exon 14 deletion caused by IVS14+1G>A) was confirmed to be catalytically inactive. Compared with WT, two variants, S534N and C29R, showed significantly higher enzymatic activity. Cells expressing S534N were more resistant to 5-FU–mediated toxicity compared with cells expressing WT DPYD. These findings support the hypothesis that selected DPYD alleles are protective against severe 5-FU toxicity, and, as a consequence, may decrease the effectiveness of 5-FU an antitumor drug in carriers. In addition, this study shows a method that may be useful for phenotyping other genetic variations in pharmacologically relevant pathways. Cancer Res; 73(6); 1958–68. ©2013 AACR.
Lot‐to‐lot variability in HLA antibody screening using a multiplexed bead‐based assay
Carrick, Danielle M. , Jenkins, Sarah M. , Goey, Steven R. De, Ploeger, Nancy A., Wilson, Gregory , Lee, Jar How, Winters, Jeffrey L. , Stubbs, James R. , Toy, Pearl, Norris, Philip J. , Gandhi, Manish J. , Winters, Jeffrey L

Mayo Clinic

Transfusion | January 11, 2013 | Volume: 53 | Issue: 9 | Pages: 1940-1947

10.1111/trf.12064 | PMID 23305156 Get It

BackgroundIdentifying antibodies to HLA (anti‐HLA) by solid‐phase assays is used to screen blood donors to mitigate transfusion‐related acute lung injury risk. Various cutoffs for detection assays have been proposed in the literature; however, these do not take into consideration lot‐to‐lot variability of commercially available assays.Study Design and MethodsSamples from 93 nontransfused males were tested using five different lots of a multiplex bead‐based anti‐HLA detection kit. A subset of 17 samples was tested on 5 days using a single lot. An additional 96 samples from donations with varied anti‐HLA levels were tested using kits from two different lots. Results were reported as a normalized background (NBG) ratio.ResultsFor the 93 nontransfused donors, NBG values generated using the reference lot were significantly higher than those obtained with three of the four comparator lots. However, for the 96 samples with low‐, moderate‐, and higher‐level anti‐HLA, Class I (CL‐I) values were 1.4 times lower and Class II (CL‐II) values were 1.2 times lower using the reference versus comparator lot. For CL‐I antibodies the between‐lot standard deviation (SD) was 1.36 (95% confidence interval [CI], 1.19‐1.60), while the between‐day SD was 1.27 (95% CI, 1.08‐1.52). Similarly, for CL‐II antibodies the between‐lot SD was 0.81 (95% CI, 0.70‐0.95), while the between‐day SD was 0.50 (95% CI, 0.43‐0.60).ConclusionsThere is interlot variability in the tested HLA detection assay as well as significant bias between lots. It may be reasonable to develop a new cutoff when a new lot is obtained.
Ubiquitin Hydrolase UCH-L1 Destabilizes mTOR Complex 1 by Antagonizing DDB1-CUL4-Mediated Ubiquitination of Raptor
Feldman, Andrew L. , Ziesmer, Steven C., Ansell, Stephen M. , Galardy, Paul J. , Hussain, Sajjad , Das, Chittaranjan , Feldman, Andrew L

Mayo Clinic

Molecular and Cellular Biology | January 8, 2013 | Volume: 33 | Issue: 6 | Pages: 1188-1197

10.1128/mcb.01389-12 | PMID 23297343 Get It

Aortic Valve Stenosis: To the Gradient and Beyond—The Mismatch Between Area and Gradient Severity
Abbas, Amr E. , Franey, Laura M., Goldstein, James A. , Lester, Steven J.

Mayo Clinic

Journal of Interventional Cardiology | January 1, 2013 | Volume: 26 | Issue: 2 | Pages: 183-194

10.1111/joic.12004 | PMID 23278313 Get It

ObjectivesThe clinical severity of aortic stenosis (AS) is based largely on symptoms. However, AS severity is primarily determined by estimating the aortic valve area (AVA) and pressure gradients (ΔP). Conditions may arise in which there is a mismatch in severity between AVA and ΔP determinations secondary to errors in measurement and/or assumption, alterations of flow, or variations in the magnitude of pressure recovery. The cause of discrepancy between area and gradient determinations must be deciphered so as to best counsel patients on the most ideal treatment strategy. (J Interven Cardiol 2013;26:183–194)
Intrinsic microvasculature of the sciatic nerve in the rat
Zamir, M. , Twynstra, Jasna , Vercnocke, Andrew J. , Welch, Ian, Jorgensen, Steve M., Ritman, Erik L., Holdsworth, David W. , Shoemaker, J. Kevin , Jorgensen, Steven M., Shoemaker, J Kevin

Mayo Clinic

Journal of the Peripheral Nervous System | December 22, 2012 | Volume: 17 | Issue: 4 | Pages: 377-384

10.1111/j.1529-8027.2012.00435.x | PMID 23279338 Get It

AbstractMicrovasculature associated with the sciatic nerve was examined using high‐resolution micro‐CT scanning in one group of rats and surgical exploration in another. The results indicate that blood supply to the sciatic nerve is an “open‐ended” system in which the vessels run longitudinally within the epineurium and connect with external vasculature primarily at junction points. Although the range of vasculature found extended down to 4–5 μ, only a few isolated vessels of this size were found, with no capillary “mesh” as such, possibly because of the close proximity of the intrinsic vessel to nerve fibers within the epineurium. While the study did not include direct measurements of flow or nerve function, the “open‐ended” pattern of vasculature found has important implications regarding the relationship between the two. Specifically, the nerve is less vulnerable to a severe or complete disruption in blood supply than it would be under a close‐ended system such as that of the heart or brain, where a severe disruption can occur with the obstruction of only a single vessel. Indeed, the pattern of vasculature found, subject to further study of vasculature at the capillary level, suggests that flow within the intrinsic vessels may be in either direction, depending on circumstances, somewhat like flow within the circle of Willis in the cerebral circulation.
Long-Term Outcomes of Proximal Row Carpectomy: A Systematic Review of the Literature
Moran, Steven, Chim, Harvey

Mayo Clinic

Journal of Wrist Surgery | December 20, 2012 | Volume: 01 | Issue: 02 | Pages: 141-148

10.1055/s-0032-1329547 | PMID 24179718 Get It

Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Mertens, Joachim C. , Fingas, Christian D., Christensen, John D. , Smoot, Rory L. , Bronk, Steven F., Werneburg, Nathan W., Gustafson, Michael P. , Dietz, Allan B. , Roberts, Lewis R. , Sirica, Alphonse E. , Gores, Gregory J. , Roberts, Lewis R , Smoot, Rory L , Dietz, Allan B

Mayo Clinic

Cancer Research | December 5, 2012 | Volume: 73 | Issue: 2 | Pages: 897-907

10.1158/0008-5472.can-12-2130 | PMID 23221385 Get It

Abstract Cancer-associated fibroblasts (CAF) are abundant in the stroma of desmoplastic cancers where they promote tumor progression. CAFs are “activated” and as such may be uniquely susceptible to apoptosis. Using cholangiocarcinoma as a desmoplastic tumor model, we investigated the sensitivity of liver CAFs to the cytotoxic drug navitoclax, a BH3 mimetic. Navitoclax induced apoptosis in CAF and in myofibroblastic human hepatic stellate cells but lacked similar effects in quiescent fibroblasts or cholangiocarcinoma cells. Unlike cholangiocarcinoma cells, neither CAF nor quiescent fibroblasts expressed Mcl-1, a known resistance factor for navitoclax cytotoxicity. Explaining this paradox, we found that mitochondria isolated from CAFs or cells treated with navitoclax both released the apoptogenic factors Smac and cytochrome c, suggesting that they are primed for cell death. Such death priming in CAFs appeared to be due, in part, to upregulation of the proapoptotic protein Bax. Short hairpin RNA-mediated attenuation of Bax repressed navitoclax-mediated mitochondrial dysfunction, release of apoptogenic factors, and apoptotic cell death. In a syngeneic rat model of cholangiocarcinoma, navitoclax treatment triggered CAF apoptosis, diminishing expression of the desmoplastic extracellular matrix protein tenascin C, suppressing tumor outgrowth, and improving host survival. Together, our findings argue that navitoclax may be useful for destroying CAFs in the tumor microenvironment as a general strategy to attack solid tumors. Cancer Res; 73(2); 897–907. ©2012 AACR.
Large Skin Defect of the Trunk Noted at Birth
Colby, Christopher E. , Moran, Steven L. , Kenney‐Jung, Daniel , Davis, Dawn Marie R. , Mardini, Samir

Mayo Clinic

NeoReviews | October 1, 2012 | Volume: 13 | Issue: 10 | Pages: e627-e631

10.1542/neo.13-10-e627 Get It

t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth
Ansell, Stephen M. , Akasaka, Takashi , McPhail, Ellen D. , Braggio, Esteban , Price-Troska, Tammy, Ziesmer, Steven C., Secreto, Frank J., Fonseca, Rafaël , Dyer, Martin J.S. , Cerhan, James R. , Novak, Anne J. , McPhail, Ellen Darcy , Manske, Michelle K. , Gupta, Mamta , Law, Mark E. , Witzig, Thomas E. , Doǧan, Ahmet , Cerhan, James R , Braggio, Esteban , Fonseca, Rafael

Mayo Clinic

Blood | September 11, 2012 | Volume: 120 | Issue: 19 | Pages: 3949-3957

10.1182/blood-2011-11-389908 | PMID 22966169 Get It

AbstractGenetic aberrations, including trisomies 3 and 18, and well-defined IGH translocations, have been described in marginal zone lymphomas (MZLs); however, these known genetic events are present in only a subset of cases. Here, we report the cloning of an IGH translocation partner on chromosome X, t(X;14)(p11.4;q32) that deregulates expression of an poorly characterized orphan G-protein–coupled receptor, GPR34. Elevated GPR34 gene expression was detected independent of the translocation in multiple subtypes of non-Hodgkin lymphoma and distinguished a unique molecular subtype of MZL. Increased expression of GPR34 was also detected in tissue from brain tumors and surface expression of GPR34 was detected on human MZL tumor cells and normal immune cells. Overexpression of GPR34 in lymphoma and HeLa cells resulted in phosphorylation of ERK, PKC, and CREB; induced CRE, AP1, and NF-κB–mediated gene transcription; and increased cell proliferation. In summary, these results are the first to identify a role for a GPR34 in lymphoma cell growth, provide insight into GPR34-mediated signaling, identify a genetically unique subset of MZLs that express high levels of GPR34, and suggest that MEK inhibitors may be useful for treatment of GPR34-expressing tumors.
Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying
Shin, Andrea , Camilleri, Michael , Busciglio, Irene, Burton, Duane, Stoner, Elizabeth, Noonan, Patrick K., Gottesdiener, Keith , Smith, Steven A., Zinsmeister, Alan R., Vella, Adrian

Mayo Clinic

Diabetes Care | September 7, 2012 | Volume: 36 | Issue: 1 | Pages: 41-48

10.2337/dc12-1128 | PMID 22961573 Get It

OBJECTIVE To investigate the pharmacokinetics (PK), pharmacodynamics, and safety of single-dose RM-131 in type 2 diabetic patients with gastrointestinal cardinal symptoms (GCSI) and previously documented delayed gastric emptying (DGE). RESEARCH DESIGN AND METHODS In a randomized crossover study, 10 female patients received RM-131 (100 μg s.c.) or placebo and underwent scintigraphic gastric emptying (GE) and colonic filling at 6 h (CF6) of a solid-liquid meal administered 30 min postdosing. Adverse events, plasma glucose, and hormonal levels were assessed. GCSI daily diary (GCSI-DD) was completed during treatments. PK was assessed in this cohort and healthy volunteers (HVs). RESULTS At screening, HbA1c was 7.2 ± 0.4% (SEM) and total GCSI-DD score was 1.32 ± 0.21. RM-131 accelerated GE t1/2 of solids (P = 0.011); mean difference (Δ) in solid GE t1/2 was 68.3 min (95% CI 20–117) or 66.1%. There were numerical differences in GE lag time, CF6 solids, and GE t1/2 liquids (all P < 0.14). With a significant (P < 0.014) order effect, further analysis of the first treatment period (n = 5 per group) confirmed significant RM-131 effects on GE t1/2 (solids, P = 0.016; liquids, P = 0.024; CF6, P = 0.013). PK was similar in DGE patients and HVs. There were increases in 120-min blood glucose (P = 0.07) as well as 30–90-min area under the curve (AUC) levels of growth hormone, cortisol, and prolactin (all P < 0.02) with single-dose RM-131. Only light-headedness was reported more on RM-131. CONCLUSIONS RM-131 greatly accelerates the GE of solids in patients with type 2 diabetes and documented DGE. PK is similar in diabetic patients and HVs.